In vivo, it competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. Its main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, thereby playing a role in the prevention and treatment of atherosclerosis and coronary heart disease. This product also reduces serum triglyceride levels and increases blood high-density lipoprotein levels.

Cyclosporine is a potent immunosuppressant that acts reversibly and specifically on lymphocytes, prolongs the survival time of allogeneic organ transplants, inhibits cell-mediated immune responses, inhibits the synthesis and release of lymphokines (including IL-2), and blocks the G0 phase and early G1 phase of the lymphocyte growth cycle. It does not inhibit erythropoiesis and does not affect phagocyte function. Patients using this product have a lower incidence of infection than those using other immunosuppressants.

Cyclosporine is a potent immunosuppressant that acts reversibly and specifically on lymphocytes. It can prolong the survival time of allogeneic organ transplants, inhibit cell-mediated immune responses, inhibit the synthesis and release of lymphokines (including IL-2), and block the G0 phase and early G1 phase of the lymphocyte growth cycle. It does not inhibit erythropoiesis and does not affect phagocyte function. Patients using this product have a lower incidence of infection than those using other immunosuppressants.

It is a new type of T lymphocyte regulator that can specifically inhibit the activity of helper T lymphocytes, but does not inhibit T lymphocytes, but promotes their proliferation. It can also inhibit the activity of B lymphocytes; it can also selectively inhibit interleukin-2 and interferon-β secreted by T lymphocytes, and can also inhibit interleukin-1 secreted by monocytes and phagocytes. While significantly inhibiting host cell immunity, it also has an inhibitory effect on humoral immunity. It can inhibit the production of anti-graft antibodies in the body, and thus has an anti-rejection effect. It does not affect the function of phagocytes and does not produce obvious bone marrow suppression.

It is a competitive inhibitor of 3-hydroxy 3-methylglutaryl coenzyme A reductase (HMG-CoA reductase). It reduces the amount of intracellular cholesterol to a certain extent by reversibly inhibiting the activity of HMG-CoA reductase, leading to an increase in the number of low-density lipoprotein (LDL) receptors on the cell surface, thereby enhancing the receptor-mediated degradation of LDL and the clearance of LDL in the blood; at the same time, it inhibits the synthesis of very low-density lipoprotein (VLDL-C) in the liver, thereby inhibiting the formation of low-density lipoprotein cholesterol (LDL-C).